{
    "clinical_study": {
        "@rank": "35209", 
        "acronym": "OHSS", 
        "arm_group": [
            {
                "arm_group_label": "Coasting", 
                "arm_group_type": "Active Comparator", 
                "description": "In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer."
            }, 
            {
                "arm_group_label": "Cabergoline", 
                "arm_group_type": "Active Comparator", 
                "description": "In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer."
            }
        ], 
        "brief_summary": {
            "textblock": "The effectiveness of cabergoline to prevent moderate-severe OHSS to coasting."
        }, 
        "brief_title": "Cabergoline Versus Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "OHSS", 
        "condition_browse": {
            "mesh_term": "Ovarian Hyperstimulation Syndrome"
        }, 
        "detailed_description": {
            "textblock": "To randomly compare two study groups under a high risk of developing OHSS to one of two arms\n      of management, either coasting for 1 to 3 days or receiving cabergoline for 8 days in ICSI\n      patients following the long luteal GnRH agonist protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age <or= 35, BMI <or= 30\n\n          2. Long protocol GnRH agonist cycles\n\n          3. Estradiol level on day of HCG >or= 3500 pg/ml\n\n          4. Retrieving more than 15 oocytes\n\n        Exclusion Criteria:\n\n          1. Male factor\n\n          2. Uterine factor"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984320", 
            "org_study_id": "92013"
        }, 
        "intervention": {
            "arm_group_label": [
                "Coasting", 
                "Cabergoline"
            ], 
            "description": "Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.", 
            "intervention_name": "ICSI", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Cabergoline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "OHSS", 
            "ICSI", 
            "Coasting", 
            "Cabergoline"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "contact": {
                "email": "yasminbassiouny@gmail.com", 
                "last_name": "Yasmin A Bassiouny, MD", 
                "phone": "+201001720751"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Study of Cabergoline Versus Coasting in GnRH Agonist Protocol in ICSI to Prevent OHSS", 
        "other_outcome": [
            {
                "description": "Number of MII oocytes collected on the day of oocyte collection", 
                "measure": "Number of Metaphase II (MII) oocytes", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Number of embryos that show signs of fertilization in each patient", 
                "measure": "Fertilization rate", 
                "safety_issue": "No", 
                "time_frame": "2 days"
            }, 
            {
                "description": "Number of embryos assessed for embryo transfer in each patient", 
                "measure": "Number of embryos", 
                "safety_issue": "No", 
                "time_frame": "3 to 5 days"
            }, 
            {
                "description": "Quality of embryos transferred to each patient whether good or poor", 
                "measure": "Quality of embryos", 
                "safety_issue": "No", 
                "time_frame": "3 to 5 days"
            }, 
            {
                "description": "The patients who have a positive quantitative Beta human chorionic gonadotrophin (BHCG) and do not continue their pregnancy with a drop in the result and start of menstruation", 
                "measure": "Implantation rate", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "patients who show an intra-uterine gestational sac with positive fetal pulsations on ultrasound 14 days after their pregnancy test", 
                "measure": "Clinical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "overall_contact": {
            "email": "yasminbassiouny@gmail.com", 
            "last_name": "Yasmin A Bassiouny, MD", 
            "phone": "+201001720751"
        }, 
        "overall_official": {
            "affiliation": "Cairo University", 
            "last_name": "Mohamed Roushdy, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Health and Population", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Symptoms of nausea, vomiting, shortness of breath, abdominal pain,abdominal distension. Ovarian size and fluid in douglas pouch by ultrasound. Haematocrit, total leucocytic count, creatinine and Estradiol level as biochemical markers. Early OHSS first 9 days after ovum pickup and late is after 9 days till 14 days (time of pregnancy test)", 
            "measure": "Rate and degree of OHSS (composite outcome)", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "reference": {
            "PMID": "23677417", 
            "citation": "Esinler I, Bozdag G, Karakocsokmensuer L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet. 2013 Nov;288(5):1159-63. doi: 10.1007/s00404-013-2875-z. Epub 2013 May 16."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984320"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cairo University", 
            "investigator_full_name": "Yasmin Ahmed Bassiouny", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Number of oocytes collected on the day of oocyte collection", 
            "measure": "Number of oocytes", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "Cairo University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cairo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}